Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
Market Cap | 864.059 Million | Shares Outstanding | 69.57 Million | Avg 30-day Volume | 568.831 Thousand |
P/E Ratio | 3.8027 | Dividend Yield | 0.0 | EPS | 1.94 |
Price to Revenue | 2.9811 | Debt to Equity | 0.8417 | EBITDA | 308.038 Million |
Price to Book Value | 1.7347 | Operating Margin | 76.9905 | Enterprise Value | 862.214 Million |
Current Ratio | 2.774 | EPS Growth | 0.051 | Quick Ratio | 2.279 |
1 Yr BETA | 0.5015 | 52-week High/Low | 20.71 / 11.57 | Profit Margin | 89.553 |
Operating Cash Flow Growth | -16.9666 | Altman Z-Score | 2.0808 | Free Cash Flow to Firm | 82.151 Million |
Earnings Report | 2023-02-08 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-01-01 | 1 | |
ZHEN MARIANNE CHIEF ACCOUNTING OFFICER |
|
38,653 | 2022-11-18 | 5 |
EDWARDS LARRY G. CEO OF LA JOLLA PHARMACEUTICAL |
|
0 | 2022-08-22 | 1 |
RAIFELD PAVEL CHIEF EXECUTIVE OFFICER |
|
504,533 | 2022-04-29 | 1 |
|
147,207 | 2022-04-25 | 1 | |
|
110,411 | 2022-04-25 | 1 | |
|
92,207 | 2022-04-25 | 1 | |
|
98,211 | 2022-04-25 | 1 | |
|
98,211 | 2022-04-25 | 1 | |
|
52,489 | 2022-04-25 | 1 | |
|
No longer subject to file | 2021-05-20 | 0 | |
HULME GEOFFREY INTERIM PRINCIPAL EXEC OFFICER |
|
No longer subject to file | 2020-05-20 | 0 |
ABERCROMBIE GEORGE B SR. VP & CHIEF COMM. OFFICER |
|
285,479 | 2018-08-20 | 0 |
WITEK THEODORE J. JR. SR. VP & CHIEF SCIENTIFIC OFF. |
|
247,767 | 2018-08-20 | 0 |
DESPARBES ERIC SVP AND CFO |
|
373,081 | 2018-05-20 | 0 |
AGUIAR MICHAEL W PRESIDENT & CHIEF EXEC OFFICER |
|
980,907 | 2017-12-04 | 0 |
FAERM MICHAEL E. SR VP & CHIEF BUSINESS OFFICER |
|
279,422 | 2017-11-20 | 0 |
|
58,278 | 2017-04-20 | 0 | |
|
161,789 | 2017-04-20 | 0 | |
|
70,554 | 2017-04-20 | 0 | |
|
52,318 | 2017-04-20 | 0 | |
|
73,805 | 2017-04-20 | 0 | |
|
73,805 | 2017-04-20 | 0 | |
|
37,083 | 2015-04-24 | 0 | |
BLUM LEONARD M SR VP, CHIEF COMM. OFFICER |
|
401,538 | 2014-08-20 | 0 |
SHAFER BRADFORD J SR VP, GEN. COUNSEL, SECRETARY |
|
443,013 | 2014-08-20 | 0 |
MAMMEN MATHAI SVP, RESEARCH & EARLY CLIN DEV |
|
334,040 | 2014-08-20 | 0 |
LEE JUNNING SR. VP, TECHNICAL OPERATIONS |
|
262,198 | 2014-08-20 | 0 |
|
825,391 | 2014-08-15 | 0 | |
|
41,000 | 2014-05-22 | 0 | |
|
36,000 | 2014-05-22 | 0 | |
|
83,935 | 2014-05-22 | 0 | |
|
776,695 | 2014-05-22 | 0 | |
|
121,679 | 2014-05-22 | 0 | |
|
33,000 | 2014-05-22 | 0 | |
|
111,794 | 2014-03-21 | 0 | |
PASQUALONE FRANK SR. VICE PRESIDENT, OPERATIONS |
|
20,000 | 2014-01-23 | 0 |
JONKER JEFFREY DAVID SENIOR VP, CORP. & BUS. DEV. |
|
15,000 | 2013-10-22 | 0 |
BRINKLEY DAVID L HEAD OF BUSINESS DEV. |
|
48,749 | 2013-05-29 | 0 |
AUNGER PAUL SECRETARY |
|
28,097,122 | 2012-11-01 | 0 |
|
33,465 | 2012-05-01 | 0 | |
INOVA TECHNOLOGY INC. PRESIDENT |
|
35,700,884 | 2012-01-22 | 0 |
|
1,572,729 | 2009-12-23 | 0 | |
KITT MICHAEL SR. VICE PRESIDENT DEVELOPMENT |
|
32,738 | 2008-06-02 | 0 |
HUMPHREY PATRICK PA EXECUTIVE VP RESEARCH |
|
85,954 | 2007-12-10 | 0 |
AUNGER PAUL SECRETARY, TREASURER |
|
295,933,739 | 2007-05-21 | 0 |
RADLY ADAM E CHIEF EXECUTIVE OFFICER |
|
568,938,076 | 2007-03-03 | 0 |
MANDELBAUM JEFFREY |
|
0 | 2006-12-11 | 0 |
LOEWENTHAL RONN |
|
21,613 | 2006-05-02 | 0 |
KIM TAE HO |
|
13,679,769 | 2006-01-20 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
INNOVIVA INC INVA | 2023-01-26 22:15:03 UTC | 4.0484 | 0.2716 | 2400000 |
INNOVIVA INC INVA | 2023-01-26 21:45:03 UTC | 4.0484 | 0.2716 | 2400000 |
INNOVIVA INC INVA | 2023-01-26 21:15:04 UTC | 4.0484 | 0.2716 | 2400000 |
INNOVIVA INC INVA | 2023-01-26 20:45:03 UTC | 4.0484 | 0.2716 | 2400000 |
INNOVIVA INC INVA | 2023-01-26 20:15:04 UTC | 4.0484 | 0.2716 | 2400000 |
INNOVIVA INC INVA | 2023-01-26 19:45:03 UTC | 4.0484 | 0.2716 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 19:15:04 UTC | 4.0484 | 0.2716 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 18:45:03 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 18:15:04 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 17:45:04 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 17:15:04 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 16:45:03 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 16:15:04 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 15:45:03 UTC | 4.0492 | 0.2708 | 2200000 |
INNOVIVA INC INVA | 2023-01-26 15:15:04 UTC | 4.0492 | 0.2708 | 2300000 |
INNOVIVA INC INVA | 2023-01-26 14:45:04 UTC | 4.0695 | 0.2505 | 2200000 |
INNOVIVA INC INVA | 2023-01-26 14:15:03 UTC | 4.0695 | 0.2505 | 2200000 |
INNOVIVA INC INVA | 2023-01-26 13:45:03 UTC | 4.0695 | 0.2505 | 2200000 |
INNOVIVA INC INVA | 2023-01-26 13:15:04 UTC | 4.0695 | 0.2505 | 2200000 |
INNOVIVA INC INVA | 2023-01-26 12:45:04 UTC | 4.0695 | 0.2505 | 2200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Index Plus All-Cap Fund | INVA | -1.0 shares, $-11.76 | 2020-03-31 | N-PORT |
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund | INVA | -30174.0 shares, $-397089.84 | 2022-08-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | INVA | -400.0 shares, $-4644.0 | 2022-09-30 | N-PORT |
JNL Series Trust- JNL Multi-Manager Alternative Fund | INVA | -40729.0 shares, $-472863.69 | 2022-09-30 | N-PORT |
AQR Funds- AQR Diversified Arbitrage Fund | INVA | -205528.0 shares, $-2386180.08 | 2022-09-30 | N-PORT |
LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio | INVA | -14605.0 shares, $-169564.05 | 2022-09-30 | N-PORT |
VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND | INVA | -357495.0 shares, $-4150516.95 | 2022-09-30 | N-PORT |
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund | INVA | -911100.0 shares, $-12354516.0 | 2022-10-31 | N-PORT |